Reirradiation and Erbitux in the HNSCC
A Phase II Study, Multicenter, to Evaluate the Efficacy and Safety of the Combination of Reirradiation - Erbitux in Subjects Previously Irradiated and With a Local Recurrent Inoperable Squamous Cell Cancer of the Head and Neck
Lead SponsorGroupe Oncologie Radiotherapie Tete et Cou
StatusCompleted No Results Posted
Indication/ConditionHead and Neck Cancer Squamous Cell
The purpose of this study is to investigate in patients with cancer of the throat and recurrent inoperable a different modality treatment consisting of radiation continuously for 5 weeks and half associated with a drug directed against a receptor on cell surfaces cancer, called Erbitux ®.
The investigators hope with this shorter treatment (1.5 weeks less than the usual treatment) to improve the antitumor efficacy without additional toxic side effects.
We hope with this treatment improved antitumor efficacy without additional toxic side effects, while being shorter than 1.5 weeks of standard therapy. But this is an hypothesis we can not meet the current state of knowledge, which justifies this study.
The main hypothesis is that this combination of reirradiation and Cetuximab give a relative gain of 15% complete response rate.
To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
Radiotherapy during 5 weeks and concurrent Erbitux once a week.
Inclusion Criteria: Patient with unresectable locoregional recurrence of squamous cell carcinoma in a previously irradiated area (at least 75% of the volume of recidivism must be in an area who have received at least 50 Gy) The entire tumor volume can be included in a radiation field without the total dose to the spinal cord more than 50 Gy (dose + dose earlier predicted) Patient with recurrent or second location in the oral cavity, oropharynx, larynx, hypopharynx, cervical lymph nodes or tissues, without distant metastases, Minimum 12 months after the end of radiotherapy previous WHO performance status: 0-1, Evaluable disease by RECIST V.1.1., Age between 18 and 75 years The patient may have received prior chemotherapy for relapse for more than five weeks, The patient may have received cetuximab for the treatment of disease but not for the first relapse, Hematologic function: ANC ≥ 1500/mm3, Platelets ≥ 100000/mm3, Normal renal function: serum creatinine ≤ 120 µmol/l and/or creatinine clearance > 60 ml/min Normal liver function: bilirubin <1.5 x ULN, alkaline phosphatase and transaminases <2.5 x ULN, Normal cardiac function, assessed clinically. History of cardiovascular disease stabilized for over 12 months Cons-Lack of medical indications in the proposed treatment, The dosimetry of previous treatment should be available and the estimated dosimetry must be performed to check the constraints, All patients of childbearing age should receive effective contraception, Membership of a social security system (or be a beneficiary of such a plan) under the terms of the Act of August 9, 2004, Signed informed consent Exclusion Criteria: Tumors of the nasal cavity and paranasal, Tumors of other histological type, Stage IV with distant metastases or multiple tumors, Time after previous radiotherapy <12 months, Less than 75% of the volume of relapse who have previously received at least 50 Gy, Any medical condition or general-cons would indicate the completion of treatment. Systemic disease or uncontrolled infection, History of cancer other than head and neck cancer, cutaneous basal cell, carcinoma in situ of the cervix Any other concurrent anticancer therapy, Patient receiving another molecule experimental Pregnant, lactating or without contraception; Persons deprived of liberty under guardianship Inability to undergo medical test for geographical, social or psychological Nasopharyngeal Neoplasms Patients with active ischemic heart disease or previous myocardial infarction within the last 12 months Late toxicity dermal or subcutaneous related to previous irradiation of grade> 2 in the scale CTCAE V.4.